Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

bio-life marketing sdn bhd - biotin; calcium pantothenate; chromium picolinate; cholecalciferol; folic acid; manganese sulphate monohydrate; nicotinamide; potassium iodide; pyridoxine hydrochloride; retinyl palmitate; riboflavin; selenomethionine; sodium ascorbate; thiamine nitrate; tocopheryl acid succinate, d-alpha; zinc oxide -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

nova laboratories sdn. bhd. - biotin; calcium carbonate; folic acid; ascorbic acid (vitamin c); calcium d-pantothenate(as vitamin b5); cyanocobalamin(as vitaminb12); d-alpha tocopherol powder; vitamin a beadlets.; docosahexaenoic acid beadlets; cholcalciferol beadlets; thiamine hydrochloride(as vitamin b1); vitamin b2 (riboflavin sodium phosphate); niacin(as vitamin b3); pyridoxine hydrochloride(as vitamin b6) -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

high valley contract manufacturing (gmp) sdn bhd - pyridoxine hcl; riboflavin; thiamine hcl; alpha lipoic acid; nicotinamide; evening primrose oil (epo); calcium caseinate; ubidecarenone (co-enzyme q10); d-alpha-tocopherol (vitamin e) -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

healol pharmaceuticals sdn. bhd. - cyanocobalamin; lecithin; nicotinamide; pyridoxine hydrochloride; riboflavin; thiamine mononitrate; dl-alpha tocopheryl acetate -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

cellgen lifesciences (m) sdn. bhd. - ascorbic acid (vitamin c); biotin; calcium pantothenate; calcium phosphate; cyanocobalamin; folic acid; magnesium phosphate; nicotinamide; pyridoxine hydrochloride; riboflavin; thiamine hydrochloride; tocopheryl acid succinate, d-alpha; calcium ascorbate dihydrate; potassium phosphate -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

megalive biosciences sdn bhd - retinyl palmitate; vitamin d3 (cholecalciferol); vitamin e (d-alpha tocopherol); thiamine nitrate; riboflavin; calcium pantothenate; pyridoxine hydrochloride; cyanocobalamin; biotin; nicotinamide; folic acid; vitamin c (ascorbic acid); cupric sulfate anhydrous; l-selenomethionine; manganese sulphate monohydrate; magnesium oxide; ferrous fumarate; zinc oxide; calcium carbonate; potassium iodide; lecithin; alpha lipoic acid; inositol; panax ginseng root extract -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

janipro (m) sdn bhd - alpha lipoic acid; calcium ascorbate; calcium pantothenate; lactobacillus reuteri; pyridoxine hydrochloride; retinyl acetate; riboflavin; sodium selenite; thiamine hydrochloride; zinc sulfate monohydrate; curcuma longa extract (turmeric); resveratrol; dl alpha tocopheryl acetate -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - hydralazine hydrochloride, quantity: 25 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; pregelatinised maize starch; colloidal anhydrous silica; magnesium stearate; sodium starch glycollate; disodium edetate; purified talc - this product accepted for registration as 'currently supplied' at the time of commencement of the act. variation to pregnancy statement in product information were approved as specified in the letter of 13 august 1992 from dr bijoy varma. indicated for the treatment of drug resistant, moderate to severe, hypertension. this drug is not a first line antihypertensive drug and is better used in combination with other therapy such as a sympatholytic agent and a diuretic. indications as at 28 november 2001 : hypertension (drug resistant, moderate to severe): as supplementary medication for use together with other antihypertensives such as "beta"-blockers and diuretics; the complementary mechanisms of action of such combined therapy enable the drugs to exert their antihypertensive effects at low doses; in addition, unwanted accompanying effects of the individual substances are either partially offset or even cancelled out.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - hydralazine hydrochloride, quantity: 50 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; sodium starch glycollate; colloidal anhydrous silica; purified talc; disodium edetate; magnesium stearate; microcrystalline cellulose; titanium dioxide; lactose monohydrate; hypromellose; indigo carmine; sunset yellow fcf; iron oxide yellow; macrogol 4000; erythrosine - this product accepted for registration as 'currently supplied' at the time of commencement of the act. amended product information (variation to pregnancy statement) was approved as specified in the letter of 13 august 92 from dr bijoy varma. indications as at 28 november 2001 : hypertension (drug resistant, moderate to severe): as supplementary medication for use together with other antihypertensives such as "beta"-blockers and diuretics; the complementary mechanisms of action of such combined therapy enable the drugs to exert their antihypertensive effects at low doses; in addition, unwanted accompanying effects of the individual substances are either partially offset or even cancelled out.

Australia - English - Department of Health (Therapeutic Goods Administration)

vitex pharmaceuticals pty ltd - ascorbic acid,betacarotene,calcium carbonate,choline bitartrate,colecalciferol,copper gluconate,cyanocobalamin,d-alpha-tocopherol,evening primrose oil,ferrous fumarate,folic acid,inositol,magnesium oxide,natural fish oil,nicotinamide,phytomenadione,potassium iodide,pyridoxine hydrochloride,riboflavin,selenomethionine,thiamine hydrochloride,zinc amino acid chelate -